drugset / Trial / NCT06351332
ZAP-IT: ZN-c3 + Carboplatin + Pembrolizumab in mTNBC
Phase 1
Terminated
7 enrolled
Filipa Lynce, MD
Merck Sharp & Dohme LLC · collabZentalis Pharmaceuticals · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
This research was done to evaluate the safety and effectiveness of a drug currently known as Azenosertib (ZN-C3) in combination with the drugs carboplatin and pembrolizumab in metastatic triple-negative breast cancer. The names of the study drugs involved in this study are: * Azenosertib (a type of WEE1 inhibitor) * Carboplatin (a type of platinum compound) * Pembrolizumab (a type of monoclonal antibody)
Timeline
- Start
- 2024-05-01
- Primary completion
- 2026-02-24
- Completion
- 2026-02-24
Outcome
Outcome not reported
Stopped: “Zentalis terminated contract due to concern for toxicity safety from previously reported serious adverse events. This study had been designed as a Phase I / Phase II study, but never reached Phase II.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azenosertib | Small molecule | 25 mg | Oral |
| Subject | Azenosertib | Small molecule | 100 mg | Oral |
| Background | Carboplatin | Small molecule | — | Intravenous |
| Background | Pembrolizumab | Monoclonal antibody | — | Intravenous |